Schizophrenia – Unmet Need – Unmet Need – Negative Symptoms of Schizophrenia (US/EU)
The negative symptoms of schizophrenia, which often coexist with the positive symptoms, include diminished emotional expression (affective flattening), diminished initiation of goal-directed behavior (avolition), paucity of speech (alogia), and/or other aspects of diminished social functioning. These symptoms negatively impact patients’ functioning and quality of life. Although the schizophrenia drug market is crowded with multiple antipsychotics, few, if any, therapies are available in the United States and Europe to treat the negative symptoms of schizophrenia. Of note, AbbVie’s Vraylar (United States) and Gedeon Richter / Recordati’s Reagila (Europe) has shown some efficacy in the treatment of predominant negative symptoms, and amisulpride is specifically approved in some European countries to treat the negative symptoms. Given that a sizeable proportion of schizophrenia patients exhibit negative symptoms and the few therapeutic options in this segment, there is high unmet need and commercial opportunity for an efficacious and safe therapy to treat the negative symptoms of schizophrenia in this underserved patient segment.
Questions answered
- Which clinical / nonclinical attributes of a therapy influence psychiatrists’ choice of treatment for the negative symptoms of schizophrenia?
- How do psychiatrists rate the performance of key current therapies in the treatment of the negative symptoms of schizophrenia?
- What is the level of need for improved treatment options in multiple psychiatry indications, including the negative symptoms of schizophrenia?
- What are the prevailing areas of unmet need in the treatment of the negative symptoms of schizophrenia?
- What are the key opportunities for drug development in this space?
- What trade-offs are acceptable to U.S. and European psychiatrists across key clinical attributes and price for a new drug to treat the negative symptoms of schizophrenia?
Product description
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 61 U.S. and 30 European psychiatrists fielded in April 2023.
Key companies: AbbVie, Gedeon Richter, Recordati, Minerva Neurosciences, Acadia Pharmaceuticals.
Key drugs: Vraylar (U.S.) / Reagila (Europe), amisulpride (Europe), aripiprazole, risperidone, olanzapine, SSRIs (i.e., fluoxetine, citalopram).
Table of contents
- Schizophrenia - Unmet Need - Unmet Need - Negative Symptoms of Schizophrenia (US/EU)
- Unmet Need - Negative Symptoms of Schizophrenia - TPP Simulator - June 2023
- Executive summary
- Introduction
- Treatment drivers and goals
- Key findings: attribute importance
- Relative importance of efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to surveyed psychiatrists' prescribing decisions in negative symptoms of schizophrenia
- Importance of efficacy attributes to prescribing decisions in negative symptoms of schizophrenia: United States
- Importance of efficacy attributes to prescribing decisions in negative symptoms of schizophrenia: Europe
- Importance of safety and tolerability attributes to prescribing decisions in negative symptoms of schizophrenia: United States
- Importance of safety and tolerability attributes to prescribing decisions in negative symptoms of schizophrenia: Europe
- Importance of convenience of administration attributes to prescribing decisions in negative symptoms of schizophrenia: United States
- Importance of convenience of administration attributes to prescribing decisions in negative symptoms of schizophrenia: Europe
- Importance of nonclinical factors to prescribing decisions in negative symptoms of schizophrenia: United States
- Importance of nonclinical factors to prescribing decisions in negative symptoms of schizophrenia: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in negative symptoms of schizophrenia: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in negative symptoms of schizophrenia: Europe
- Product performance against treatment drivers and goals
- Key findings
- Overall performance of key therapies for negative symptoms of schizophrenia: United States
- Overall performance of key therapies for negative symptoms of schizophrenia: Europe
- Mean overall performance of key therapies for negative symptoms of schizophrenia: United States and Europe
- Relative performance of key therapies for negative symptoms of schizophrenia across select efficacy attributes: United States
- Relative performance of key therapies for negative symptoms of schizophrenia across select efficacy attributes: Europe
- Relative performance of key therapies for negative symptoms of schizophrenia across select safety and tolerability attributes: United States
- Relative performance of key therapies for negative symptoms of schizophrenia across select safety and tolerability attributes: Europe
- Relative performance of key therapies for negative symptoms of schizophrenia across select convenience of administration attributes: United States
- Relative performance of key therapies for negative symptoms of schizophrenia across select convenience of administration attributes: Europe
- Relative performance of key therapies for negative symptoms of schizophrenia across select nonclinical attributes: United States
- Relative performance of key therapies for negative symptoms of schizophrenia across select nonclinical attributes: Europe
- Assessment of unmet need
- Key findings: unmet need in in negative symptoms of schizophrenia
- Surveyed psychiatristsu2019 satisfaction with the performance of key therapies for negative symptoms of schizophrenia on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: United States
- Surveyed psychiatristsu2019 satisfaction with the performance of key therapies for negative symptoms of schizophrenia on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed psychiatrists' ascribed level of unmet need across key efficacy attributes in negative symptoms of schizophrenia: United States
- Surveyed psychiatrists' ascribed level of unmet need across key efficacy attributes in negative symptoms of schizophrenia: Europe
- Surveyed psychiatrists' ascribed level of unmet need across key safety and tolerability attributes in negative symptoms of schizophrenia: United States
- Surveyed psychiatrists' ascribed level of unmet need across key safety and tolerability attributes in negative symptoms of schizophrenia: Europe
- Surveyed psychiatrists' ascribed level of unmet need across key convenience of administration attributes in negative symptoms of schizophrenia: United States
- Surveyed psychiatrists' ascribed level of unmet need across key convenience of administration attributes in negative symptoms of schizophrenia: Europe
- Surveyed psychiatrists' ascribed level of unmet need across key nonclinical factors in negative symptoms of schizophrenia: United States
- Surveyed psychiatrists' ascribed level of unmet need across key nonclinical factors in negative symptoms of schizophrenia: Europe
- Key findings: unmet need in in negative symptoms of schizophrenia and related indications
- Surveyed psychiatrists' ascribed level of unmet need in negative symptoms of schizophrenia and related indications: United States
- Surveyed psychiatrists' ascribed level of unmet need in negative symptoms of schizophrenia and related indications: Europe
- Opportunity analysis
- Areas of opportunity in the negative symptoms of schizophrenia market and emerging therapy insights
- Opportunity: a therapy offering improvement in negative symptoms in schizophrenia patients
- Opportunity: a therapy offering improvement in functioning in patients with the negative symptoms of schizophrenia
- Opportunity: an efficacious therapy offering an improved safety and tolerability profile in patients with the negative symptoms of schizophrenia
- Areas of opportunity in the negative symptoms of schizophrenia market and emerging therapy insights
- Target product profiles
- Appendix
